| |
|
門田 守人 |
がん研有明病院・病院長 |
| 消化器外科 |
| Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Ritchie SA1, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, et al. BMC Cancer. 2013 Sep 12;13:416. |
| 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. Hepatol Res. 2012 Feb;42(2):150-65. |
| Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan. Br J Surg. 2011 Apr;98(4):552-7. |
|
| |
|
今井 浩三 |
東京大学医科学研究所・特任教授 |
| 分子腫瘍学、臨床腫瘍学 |
| Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Nasuno M, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nakagaki S, Watanabe S, Idogawa M, Yamashita K, Naishiro Y, Adachi Y, Suzuki H, Fujimiya M, Imai K, Shinomura Y. Stem Cells 2014.32(4):913-925, doi: 10.1002/stem.1594. |
| Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y. Cancer Res. 2012; 72(5):1126-1136. |
| Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R, Kai M, Yamano HO, Sasaki Y, Tokino T, Shinomura Y, Imai K, Toyota M. Cancer Res. 2011; 71: 5646-5658. |
|
| |
|
大津 敦 |
国立がん研究センター先端医療開発センター長 |
| 腫瘍内科 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Ohtsu A, et al, Lancet 376: 687-697, 2010 |
| TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Lancet Oncol. 13(10):993-1001, 2012 |
| Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). Ohtsu A, Shimada Y, Shirao K, et al. J Clin Oncol, 21: 54-59, 2003 |
|
| |
|
清木 元治 |
高知大学・特任教授 |
| がんの分子生物学 |
Seiki, M., Eddy, R., Shows, T.B., and Yoshida, M. (1984). Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 309, 640-642.
|
| Seiki, M., Hikikoshi, A., Taniguchi, T., and Yoshida, M. (1985). Expression of the pX gene of HTLV-I: general splicing mechanism in the HTLV family. Science 228, 1532-1534. |
Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
|
|
| |
|
坂 英雄 |
国立病院機構名古屋医療センター
呼吸器科がん総合診療部長 |
| 呼吸器内科学，臨床腫瘍学 |
| Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T. Invest New Drugs. 2013 Oct;31(5):1275-82. |
| Rationale and design of the Japan molecular epidemiology for lung cnacer study. Kawaguchi T, Ando M, Ito N, Isa S, Tamiya A, Shimizu S, Saka H, Kubo A, Koh Y, Matsumura A. Lung Cancer. 2013 Sep;14(5):596-600. |
| Histology and Smoking Status Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer:: Results of West Japan Oncology Group (WJOG) Study 3906L. Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. J Thorac Oncol. 2013 Jun;8(6):753-8. |
|
| |
|
野田 哲生 |
公益財団法人がん研究会
代表理事・常務理事 がん研究所 所長 |
| 分子遺伝学 |
| H. Takeshima, M. Iino, H. Takekura, M. Nishi, J. Kuno, O. Minowa, H. Takano and T. Noda. (1994) Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. Nature, 369: 556-559. |
| H. Shibata, K. Toyama, H. Shioya, M. Ito, M. Hirota, S. Hasegawa, H. Matsumoto, H. Takano, T. Akiyama, K. Toyoshima, R. Kanamaru, Y. Kanegae, I. Saito, Y. Nakamura, K. Shiba and T. Noda. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science, 278: 120-123. |
| R. Yao, Y. Kondoh, Y. Natsume, H. Yamanaka, M. Inoue, H. Toki, R. Takagi, T. Shimizu, T. Yamori, H. Osada and T. Noda. (2014) A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene, 33: 4242-4252. |
|
| ○ |
|
福岡 正博 |
和泉市立病院 総長 |
| がん化学療法、肺がんの治療、がんトランスレーショナルリサーチ |
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Fukuoka M, Yano S, et al., J Clin Oncol. 21: 2237-2246, 2003. |
| Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ohe Y, Fukuoka M, et al., Ann Oncol. 18: 317-323, 2007 |
| Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Mok TS, et al., J Clin Oncol. 29: 2866-2874, 2011. |
|
